GW Pharmaceuticals Plc ADS (GWPH)

[john1311]

GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -
- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –
- Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 -

LONDON and CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full year 2020 and key priorities for 2021. Justin Gover, GW’s Chief Executive Officer, expects to discuss these updates as part of a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12th at 10:00 a.m. ET.

https://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-provides-preliminary-fourth-quarter-and-full